Get the Stockscreener App
8.24
0.00%
0.00
After Hours:
8.25
0.010
+0.12%
Agenus Inc stock is traded at $8.24, with a volume of 986.24K.
It is up +0.00% in the last 24 hours and down -0.72% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$8.24
Open:
$8.14
24h Volume:
986.24K
Relative Volume:
0.25
Market Cap:
$370.88M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
4.9356
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+7.57%
1M Performance:
-0.72%
6M Performance:
+157.50%
1Y Performance:
+92.07%
1-Day Range:
$7.99
$8.38
1-Week Range:
$7.50
$8.38
52-Week Range:
$2.71
$8.85
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
8.24 | 337.12M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Immigrant Entrepreneur Garo H. Armen Of Agenus Inc. Riccardo Braschi (I0EURkuuPl) - Mshale
New Phase 2 NEST Results Support Neoadjuvant BOT+BAL in Colon Cancer – Agenus - Oncodaily
Agenus reports survival data for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Yahoo Finance
Agenus Inc: Shareholders Revolt Over Executive Pay! My Thoughts. Tampa Bay Rays (VzxHMd1TNP) - Mshale
Agenus Inc.AGEN Stock Chart Technical Analysis For 09-21-2020 Sporting Cp (0os72ROBex) - Mshale
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Yahoo Finance
Agenus Reports No Recurrences and Deep Pathologic Responses With Neoadjuvant BOT+BAL in Resectable Colon Cancer - Oncodaily
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (9cYwfB9Crl) - Mshale
Agenus | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks Donald Gibb (Gf1su3sDdD) - Mshale
AGEN Stock Analysis | Agenus Inc Stock Update & Chart Breakdown Traffic Stop (vDz5v0ltyg) - Mshale
Bold Move By Agenus: Cutting Costs By 60% To Focus On Groundbreaking Cancer Treatments Nikoloz Basilashvili (41VwNJliWR) - Mshale
Insider Trading AGEN Agenus Inc 2021 05 18 Blowing Dust Advisory (aETsN3n1J0) - Mshale
Agenus Inc AGEN CEO Garo Armen On Q4 2019 Results David Muir (NjcFXnx049) - Mshale
Agenus Inc (AGEN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
AGEN Stock TUESDAY MADNESS! (news Update) Agenus Stock Analysis Best Broker Review Challenge Cup Final 2026 (5MyfQl06Kh) - Mshale
Agenus Inc. (AGEN) Latest Stock News & Headlines - Yahoo Finance
Agenus extends $24.75 million loan maturity, adjusts payment terms with Ocean 1181 - Investing.com
Form 8K Agenus Inc For: 18 August By Investing.com - Investing.com South Africa
Agenus Extends $24.75M Term Loan to 2029 at 13% With Ocean 1181; Partly Payable in Stock - TradingView
Agenus (NASDAQ: AGEN) to pay part of 13% loan interest in stock - Stock Titan
Agenus Inc. Extends $24.75 Million Loan Maturity to 2029 with Modified Terms - Kalkine Media
AGEN Q2 2026 Earnings: EPS Misses Estimates by 119.61% as Shares Slide 2.32%EBITDA Estimate Trend - Vinanet
AGENUS INC SEC Filing (Aug 17, 2026) - Stock Titan
Agenus Puts Its BOT+BAL Cancer Combo To The Test - Finimize
Renaissance Technologies LLC Sells 257,900 Shares of Agenus Inc. $AGEN - MarketBeat
HC Wainwright Estimates Agenus' Q3 Earnings (NASDAQ:AGEN) - MarketBeat
Agenus grants CEO Garo Armen 1,971,500 performance-based stock options at $7.78 per share - Bitget
Agenus (NASDAQ: AGEN) awards 1.97M performance-tied stock options to CEO - Stock Titan
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL S - The National Law Review
Form 8K Agenus Inc For: 11 August By Investing.com - Investing.com South Africa
Agenus appoints Marco Tullio Marcucci to board of directors By Investing.com - Investing.com Nigeria
Agenus appoints Marco Tullio Marcucci to board of directors - Investing.com
Agenus Director Brian Corvese Granted 100,000 Stock Options Under 2019 Equity Incentive Plan - Kalkine Media
Agenus Director Thomas L. Harrison Granted 50,000 Stock Options Under 2019 Equity Incentive Plan - Kalkine Media
AGENUS appoints Marco Tullio Marcucci to its Board as Class II director - TradingView
Agenus Inc. (AGEN) expands board, appoints Marco Tullio Marcucci as Class II director - Stock Titan
Agenus Inc (AGEN) awards 50,000 stock options to director Thomas L. Harrison - Stock Titan
Agenus (AGEN) director Brian Corvese receives 100,000 stock options at $7.78 - Stock Titan
Wainwright cuts Agenus stock price target to $25 on higher costs - Investing.com Nigeria
Wainwright cuts Agenus stock price target to $25 on higher costs By Investing.com - Investing.com India
HC Wainwright Issues Positive Outlook for Agenus Earnings - MarketBeat
AGEN Stock (Agenus Stock) AGEN STOCK Analysis AGEN STOCK PREDICTION In AGEN Stock News Today Bella Vaughn Hunter Johnson Engagement (u90ZBraz9y) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Cigarette (l3DDhgoK4D) - Mshale
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agenus (AGEN) Stock Drops As One Off Gain Masks Profit Slip - Sahm
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Agenus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):